TERN
Terns Pharmaceuticals Inc
NASDAQ: TERN · HEALTHCARE · BIOTECHNOLOGY
$52.92
-0.04% today
Updated 2026-04-29
Market cap
$6.11B
P/E ratio
—
P/S ratio
302.64x
EPS (TTM)
$-1.03
Dividend yield
—
52W range
$3 – $53
Volume
6.6M
Terns Pharmaceuticals Inc (TERN) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $1.00M | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | -100.0% | — | — | — |
| Cost of revenue | $65000.00 | $195000.00 | $394000.00 | $512000.00 | $1.03M | $881000.00 | — | — |
| Gross profit | $-65000.00 | $-195000.00 | $-394000.00 | $1.00M | $-1.03M | $-881000.00 | — | — |
| Gross margin | — | — | — | 100.0% | — | — | — | — |
| R&D | $14.55M | $61.53M | $28.03M | $31.31M | $39.62M | $63.50M | $70.11M | $77.89M |
| SG&A | $3.90M | $8.66M | $9.00M | $19.55M | $22.41M | $39.06M | $31.76M | $32.23M |
| Operating income | $-18.45M | $-70.20M | $-37.02M | $-49.86M | $-62.03M | $-102.56M | $-101.87M | $-110.12M |
| Operating margin | — | — | — | -4986.0% | — | — | — | — |
| EBITDA | $-18.39M | $-68.64M | $-36.63M | $-49.35M | $-61.00M | $-101.68M | $-100.97M | $-110.12M |
| EBITDA margin | — | — | — | -4934.8% | — | — | — | — |
| EBIT | $-18.45M | $-68.84M | $-37.02M | $-49.86M | $-62.03M | $-102.56M | $-101.87M | — |
| Interest expense | $0.00 | $1.57M | $2.21M | $722000.00 | $2.04M | — | — | — |
| Income tax | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-17.71M | $-68.82M | $-29.35M | $-50.16M | $-60.34M | $-90.21M | $-88.85M | $-96.21M |
| Net income growth (YoY) | — | -288.6% | +57.3% | -70.9% | -20.3% | -49.5% | +1.5% | -8.3% |
| Profit margin | — | — | — | -5015.8% | — | — | — | — |